PYXS MEXC RealStocks
Own real PYXS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-16 13:43:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Pyxis Oncology, Inc. (PYXS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.62, with a market capitalization of $188.98M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.03 to $5.55. This page covers its latest market performance, valuation, price trends and company information.
$188.98M | |
$1.57 | |
$1.63 | |
$1.57 | |
$1.58 | |
21.00 | |
997.89K | |
-- | |
$5.55 | |
$1.03 | |
-- | |
-- |
Pyxis Oncology, Inc. (PYXS) is trading at $1.62 in pre-market trading as of 2026-11-16 13:39:00, up 2.53% ($0.04) from the previous close of $1.58
Pre-market trading shows how investors are pricing PYXS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Pyxis Oncology, Inc. (PYXS) moved from $1.61 to $1.62, representing a gain of 0.62% ($0.01).
The stock traded between $1.50 and $1.80 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 744.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 13.1%
PYXS is currently trading at $1.62, placing it 13.1% of the way from its 52-week low of $1.03 to its 52-week high of $5.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 56 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pyxis Oncology, Inc. (PYXS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PYXS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PYXS shares and USD.
PYXS Shares to USD
1.00 PYXS shares = 1.62 USD
Calculations are estimates based on the latest available price and are for reference only.